Treating a systemic disease as a local one: failure points of current pancreatic cancer management and a multimodal, biology-guided framework for redesign

Pancreatic ductal adenocarcinoma remains among the most lethal solid tumors, with 5-year survival near 13% despite decades of incremental change, and current management continues to be organized around anatomic resectability and a chemotherapy backbone applied largely without regard to tumor biology. This article advances the thesis that the dominant paradigm underperforms because it treats a systemic, molecularly convergent, multi-compartment disease as though it were a local one. We first summarize the real advances of the past decade—in surgery, systemic therapy, molecular profiling, and immunotherapy—and then identify five interlocking failure points that persist despite them: (i) selection by vessel anatomy, judged on imaging criteria that are read inconsistently and that classify inaccurately even where read consistently, and applied to splanchnic veins without accounting for their baseline variability and tumor-associated thrombosis; (ii) occult metastasis and the resulting limits of local cure for the systemic majority, evidenced by the gap between complete resection and durable survival and by early distant recurrence; (iii) the addition of radiotherapy, which improves local control without extending survival; (iv) chemotherapy chosen without reference to a validated prognostic classical/basal-like distinction, although prospective subtype-directed regimen selection has not yet improved outcomes in randomized testing; and (v) a sequential, non-integrated structure in which systemic and immune therapy are deferred and no definitive path exists for the roughly 80% who are not surgical candidates. We then propose a multimodal, biology-guided framework that answers each failure point, with every component graded on an explicit evidence scale: corrected tumor-suppressor gene therapy matched to lesion type, a systemic backbone combining renin-angiotensin system-pathway inhibition with immunogenically sequenced chemotherapy and personalized neoantigen vaccination, in-situ immune conversion of an accessible tumor by cryoablation with local priming and natural killer (NK) cell delivery, and front-end biological patient selection. The framework is conceptual rather than product-specific; we specify its rationale, its integration in time, a staged first-in-human development program, and the studies required to test it. The objective is to convert local disease into systemic benefit—a step the current paradigm is not designed to take.